Tacrolimus, Indian WHO-GMP supply for transplant immunosuppression, prescribed and dispensed brand-consistent for a narrow-therapeutic-index medicine.

Across the transplant and dermatology range. Immediate-release hard capsules at 0.5, 1 and 5 mg (the Prograf-equivalent, dosed twice daily and titrated to whole-blood trough levels); prolonged-release once-daily capsules at 0.5, 1, 3 and 5 mg where the destination protocol uses the modified-release schedule; granules for oral suspension at 0.2 mg and 1 mg for paediatric transplant recipients; and cutaneous ointment at 0.03% and 0.1% for atopic dermatitis. Packs are Alu-Alu blister or HDPE bottle for capsules and aluminium tube for ointment. All from Indian WHO-GMP-certified facilities. Because tacrolimus is a narrow-therapeutic-index medicine, we supply a single consistent brand and formulation per programme rather than mixing lines within a treatment course.

No. M Care is a merchant exporter. We supply tacrolimus from Indian WHO-GMP-certified manufacturers (the major Indian generic lines include Dr Reddy's, Cipla, Intas, Panacea Biotec, Biocon and others) and handle export, documentation, registration support, freight and pharmacovigilance set-up. We do not run a manufacturing plant ourselves. For a buyer that means we route each order to a single consistent WHO-GMP line for the destination, hold the brand and formulation steady across the treatment course as the narrow-therapeutic-index guidance requires, and carry the regulatory and logistics paperwork.

Because tacrolimus is a narrow-therapeutic-index drug with high inter- and intra-individual pharmacokinetic variability, so even small differences in absorbed dose can tip a patient into toxicity or graft rejection. Since June 2012 the UK MHRA has advised that all oral tacrolimus products are prescribed and dispensed by brand name only, to minimise inadvertent switching between products, which has been associated with reports of toxicity and graft rejection; other regulators take the same line. The practical consequence for supply is that a patient is kept on one named formulation with its corresponding dosing schedule, and any change of product is a deliberate clinical decision accompanied by repeat trough monitoring. We supply a single consistent line per programme for exactly this reason and we do not substitute mid-course.

Tacrolimus is the first-line cornerstone of maintenance immunosuppression after solid-organ transplantation. It is given for prophylaxis of allograft rejection in kidney, liver and heart transplant recipients (and is widely used in lung, pancreas and intestinal transplantation), typically in standard triple therapy with mycophenolate and a corticosteroid, and it is used to treat allograft rejection that is resistant to other immunosuppressants. Dosing is individualised to whole-blood trough (C0) levels rather than to a fixed milligram dose. Separately, the topical ointment treats moderate-to-severe atopic dermatitis as a calcineurin-inhibitor alternative to topical corticosteroids, used second-line and intermittently. A specialist medicine throughout, requiring therapeutic drug monitoring on the systemic side.

Several priority signals govern use. Dose-related nephrotoxicity is the dominant chronic toxicity of calcineurin inhibitors and is the main reason trough levels are kept as low as rejection risk allows. Neurotoxicity ranges from common tremor, headache and insomnia to rare seizures and posterior reversible encephalopathy syndrome. New-onset diabetes after transplant (post-transplant diabetes mellitus), hypertension, hyperkalaemia, hypomagnesaemia and QT-interval prolongation are recognised metabolic and cardiac effects. As an immunosuppressant it raises the risk of opportunistic infection (CMV, BK polyomavirus, Pneumocystis jirovecii) and of malignancy, including post-transplant lymphoproliferative disorder and skin cancers. The interaction profile is extensive and clinically important because tacrolimus is metabolised by CYP3A4 / CYP3A5 and is a P-glycoprotein substrate: azole antifungals, macrolide antibiotics, calcium-channel blockers, protease inhibitors and grapefruit raise levels, while rifampicin, enzyme-inducing anticonvulsants and St John's Wort lower them, so any change in co-medication is accompanied by repeat trough monitoring. The topical product carries a boxed warning regarding a theoretical malignancy risk and is used second-line, not continuously long-term.

Transplant immunosuppressants are needed wherever there is an organ-transplant programme, and generic immediate-release tacrolimus is lawfully available across most of them. Sub-Saharan Africa, anchored by South Africa (SAHPRA), which runs the continent's largest transplant programme, plus the emerging kidney-transplant centres across Nigeria (NAFDAC), Kenya (PPB), Ghana (FDA), Ethiopia (EFDA) and Egypt (EDA). GCC transplant centres (NUPCO and SFDA in Saudi Arabia, MoHAP / DHA / DoH in the UAE, and the Kuwait, Qatar, Oman and Bahrain ministries) procuring through licensed importers. ASEAN and South Asia (Philippines FDA, Vietnam DAV, Indonesia BPOM, Bangladesh DGDA, Sri Lanka NMRA) and Latin America (Brazil ANVISA, Mexico COFEPRIS). UK and EU supply runs through the brand-prescribing framework. The topical ointment has broader dermatology demand independent of the transplant channel. We do not supply into India, and we verify the per-destination position before quoting. Full coverage at markets.

Batch-specific Certificate of Analysis (HPLC tacrolimus assay, related substances per Ph.Eur./USP, dissolution profile, content uniformity, water content, capsule or ointment-specific tests), Method of Analysis, bioequivalence study report against the Prograf reference for new registrations (held to the tighter narrow-therapeutic-index acceptance criteria), Certificate of Pharmaceutical Product (CoPP) from CDSCO India, WHO-GMP certificate, manufacturing licence, Certificate of Origin, and a destination-language pack insert carrying the brand-consistency note, the therapeutic-drug-monitoring requirement, the CYP3A interaction table and the post-transplant infection and malignancy counselling text. Temperature and humidity logs from pre-dispatch through on-arrival. CTD Module 3 dossier available against an NDA, see dossier preparation.